REGENERON PHARMACEUTICALS, INC. Insider Trading for February 2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REGENERON PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in REGENERON PHARMACEUTICALS, INC. for February 2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Option Exercise | M | 52.03 | 25,000 | 1,300,750 | 38,079 | |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Option Exercise | M | 52.03 | 25,000 | 1,300,750 | 38,079 | |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 468.56 | 31 | 14,525 | 11,380 | 11.4 K to 11.4 K (-0.27 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 465.42 | 227 | 105,650 | 11,411 | 11.6 K to 11.4 K (-1.95 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 464.14 | 126 | 58,482 | 11,638 | 11.8 K to 11.6 K (-1.07 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 463.10 | 123 | 56,961 | 11,764 | 11.9 K to 11.8 K (-1.03 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 462.15 | 1 | 462 | 11,887 | 11.9 K to 11.9 K (-0.01 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 461.24 | 614 | 283,201 | 11,888 | 12.5 K to 11.9 K (-4.91 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 460.34 | 252 | 116,006 | 12,502 | 12.8 K to 12.5 K (-1.98 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 459.47 | 692 | 317,953 | 12,754 | 13.4 K to 12.8 K (-5.15 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 458.59 | 460 | 210,951 | 13,446 | 13.9 K to 13.4 K (-3.31 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 457.27 | 141 | 64,475 | 13,906 | 14 K to 13.9 K (-1.00 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 456.63 | 743 | 339,276 | 14,047 | 14.8 K to 14 K (-5.02 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 455.56 | 2,967 | 1,351,647 | 14,790 | 17.8 K to 14.8 K (-16.71 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 454.58 | 102 | 46,367 | 17,757 | 17.9 K to 17.8 K (-0.57 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 453.45 | 113 | 51,240 | 17,859 | 18 K to 17.9 K (-0.63 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 452.08 | 130 | 58,770 | 17,972 | 18.1 K to 18 K (-0.72 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 451.47 | 233 | 105,193 | 18,102 | 18.3 K to 18.1 K (-1.27 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 450.10 | 125 | 56,263 | 18,335 | 18.5 K to 18.3 K (-0.68 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 449.53 | 236 | 106,089 | 18,460 | 18.7 K to 18.5 K (-1.26 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 448.86 | 240 | 107,726 | 18,696 | 18.9 K to 18.7 K (-1.27 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 445.91 | 120 | 53,509 | 18,936 | 19.1 K to 18.9 K (-0.63 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 444.65 | 490 | 217,879 | 19,056 | 19.5 K to 19.1 K (-2.51 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 443.67 | 264 | 117,129 | 19,546 | 19.8 K to 19.5 K (-1.33 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 440.24 | 395 | 173,895 | 19,810 | 20.2 K to 19.8 K (-1.95 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 439.73 | 231 | 101,578 | 20,205 | 20.4 K to 20.2 K (-1.13 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 438.63 | 256 | 112,289 | 20,436 | 20.7 K to 20.4 K (-1.24 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 437.41 | 480 | 209,957 | 20,692 | 21.2 K to 20.7 K (-2.27 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 436.43 | 348 | 151,878 | 21,172 | 21.5 K to 21.2 K (-1.62 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 435.93 | 209 | 91,109 | 21,520 | 21.7 K to 21.5 K (-0.96 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Payment of Exercise | F | 451.89 | 14,651 | 6,620,640 | 21,729 | 36.4 K to 21.7 K (-40.27 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Buy | M | 52.03 | 25,000 | 1,300,750 | 36,380 | 11.4 K to 36.4 K (+219.68 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Option Exercise | M | 33.42 | 2,500 | 83,550 | 12,500 | |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 455.00 | 500 | 227,500 | 9,000 | 9.5 K to 9 K (-5.26 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 450.00 | 500 | 225,000 | 9,500 | 10 K to 9.5 K (-5.00 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 457.00 | 400 | 182,800 | 3,700 | 4.1 K to 3.7 K (-9.76 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 450.00 | 400 | 180,000 | 4,100 | 4.5 K to 4.1 K (-8.89 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 455.00 | 300 | 136,500 | 2,400 | 2.7 K to 2.4 K (-11.11 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 450.00 | 300 | 135,000 | 2,700 | 3 K to 2.7 K (-10.00 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 460.00 | 2,500 | 1,150,000 | 115,415 | 117.9 K to 115.4 K (-2.12 %) |
| Feb 28 2020 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Buy | M | 33.42 | 2,500 | 83,550 | 117,915 | 115.4 K to 117.9 K (+2.17 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 1,000 | 272,700 | 54,500 | |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 1,000 | 272,700 | 55,500 | |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 460.05 | 34 | 15,642 | 24,973 | 25 K to 25 K (-0.14 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 458.35 | 27 | 12,375 | 25,007 | 25 K to 25 K (-0.11 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 457.23 | 25 | 11,431 | 25,034 | 25.1 K to 25 K (-0.10 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 456.67 | 10 | 4,567 | 25,059 | 25.1 K to 25.1 K (-0.04 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 455.37 | 32 | 14,572 | 25,069 | 25.1 K to 25.1 K (-0.13 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 454.85 | 18 | 8,187 | 25,101 | 25.1 K to 25.1 K (-0.07 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 453.36 | 44 | 19,948 | 25,119 | 25.2 K to 25.1 K (-0.17 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 452.04 | 10 | 4,520 | 25,163 | 25.2 K to 25.2 K (-0.04 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 455.13 | 17 | 7,737 | 25,173 | 25.2 K to 25.2 K (-0.07 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 454.67 | 4 | 1,819 | 25,190 | 25.2 K to 25.2 K (-0.02 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 453.60 | 16 | 7,258 | 25,194 | 25.2 K to 25.2 K (-0.06 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 450.80 | 35 | 15,778 | 25,210 | 25.2 K to 25.2 K (-0.14 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 449.50 | 54 | 24,273 | 25,245 | 25.3 K to 25.2 K (-0.21 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 448.54 | 18 | 8,074 | 25,299 | 25.3 K to 25.3 K (-0.07 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 447.11 | 37 | 16,543 | 25,317 | 25.4 K to 25.3 K (-0.15 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 445.35 | 11 | 4,899 | 25,354 | 25.4 K to 25.4 K (-0.04 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 444.03 | 12 | 5,328 | 25,365 | 25.4 K to 25.4 K (-0.05 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 438.00 | 10 | 4,380 | 25,377 | 25.4 K to 25.4 K (-0.04 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 447.30 | 800 | 357,840 | 25,387 | 26.2 K to 25.4 K (-3.05 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,000 | 272,700 | 26,187 | 25.2 K to 26.2 K (+3.97 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 406.59 | 786 | 319,580 | 25,187 | 26 K to 25.2 K (-3.03 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,000 | 272,700 | 25,973 | 25 K to 26 K (+4.00 %) |
| Feb 25 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Option Exercise | M | 273.67 | 2,000 | 547,340 | 250 | |
| Feb 25 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 419.03 | 44 | 18,437 | 643 | 687 to 643 (-6.40 %) |
| Feb 25 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 419.00 | 1,956 | 819,564 | 687 | 2.6 K to 687 (-74.01 %) |
| Feb 25 2020 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Buy | M | 273.67 | 2,000 | 547,340 | 2,643 | 643 to 2.6 K (+311.04 %) |
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 500 | 136,350 | 56,500 | |
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 407.66 | 5 | 2,038 | 24,973 | 25 K to 25 K (-0.02 %) |
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 402.30 | 4 | 1,609 | 24,978 | 25 K to 25 K (-0.02 %) |
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 401.70 | 8 | 3,214 | 24,982 | 25 K to 25 K (-0.03 %) |
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 400.54 | 21 | 8,411 | 24,990 | 25 K to 25 K (-0.08 %) |
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 399.89 | 22 | 8,798 | 25,011 | 25 K to 25 K (-0.09 %) |
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 398.63 | 47 | 18,736 | 25,033 | 25.1 K to 25 K (-0.19 %) |
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 402.34 | 393 | 158,120 | 25,080 | 25.5 K to 25.1 K (-1.54 %) |
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 500 | 136,350 | 25,473 | 25 K to 25.5 K (+2.00 %) |
| Feb 10 2020 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 382.83 | 1,000 | 382,830 | 9,643 | 10.6 K to 9.6 K (-9.40 %) |